Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC25A1 | P53007 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.65 |
| ▸ | MAPT | P10636 | 6/20 | 0.63 |
| ▸ | POLB | P06746 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.59 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | WDR5 | P61964 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30252330 | 1.00 | SLC25A1 (1.00) | SLC25A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL11172199 | 0.82 | POLB (0.77) | SLC25A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL7443125 | 0.81 | SLC25A1 (0.68) | SLC25A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL10422318 | 0.80 | SLC25A1 (0.66) | SLC25A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL30515744 | 0.78 | SLC25A1 (0.64) | SLC25A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL30515745 | 0.78 | SLC25A1 (0.64) | SLC25A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL8366106 | 0.78 | CASP3 (0.81) | SLC25A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL30515750 | 0.78 | MAPK1 (0.73) | SLC25A1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL11772392 | 0.78 | SLC25A1 (0.64) | SLC25A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL27179628 | 0.78 | MAPT (0.84) | SLC25A1MEN1KMT2AMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4181911-A1 | THE ROLE OF PMCIC IN THE TUMOR MICROENVIRONMENT | Universitätsklinikum Regensburg (DE) | 2023-05-24 | — | — | EP | claimed |
| WO-2022013295-A1 | THE ROLE OF PMCIC IN THE TUMOR MICROENVIRONMENT | UNIVERSITÄTSKLINIKUM REGENSBURG (DE) | 2022-01-20 | — | — | WO | claimed |
| US-20180028647-A1 | MODIFICATIONS OF THERAPEUTIC AGENTS FOR ENHANCED DELIVERY TO TARGET SITES | CLARIA ODIN LLC | 2018-02-01 | — | — | US | claimed |
| US-20170349949-A1 | METHODS OF SELECTING SUBJECTS FOR TREATMENT WITH METABOLIC MODULATORS | CLARIA PARTIKULA LLC | 2017-12-07 | — | — | US | claimed |
| US-12133720-B2 | Methods and compositions for restoring homeostatic capacity of a subject | Palo Alto Investors LP (US) | 2024-11-05 | — | — | US | disclosed |
| US-20240358783-A1 | METHOD AND SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF A PSYCHEDELIC AGENT | LCT TECHNOLOGIES LLC | 2024-10-31 | — | — | US | disclosed |
| EP-4313007-A1 | TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT | Lyfe CHNG, LLC (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4181911-A1 | THE ROLE OF PMCIC IN THE TUMOR MICROENVIRONMENT | Universitätsklinikum Regensburg (DE) | 2023-05-24 | — | — | EP | disclosed |
| US-20230026731-A1 | TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT | LCT TECHNOLOGIES LLC | 2023-01-26 | — | — | US | disclosed |
| WO-2022221072-A1 | TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT | MYCRODOSE THERAPEUTICS INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| US-20220323389-A1 | TREATING NON-ALCOHOLIC FATTY LIVER DISEASE AND INFLAMMATORY STEATOHEPATITIS WITH SLC25A1 INHIBITORS | GEORGETOWN UNIVERSITY (US) | 2022-10-13 | — | — | US | disclosed |
| WO-2022212789-A1 | TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT | MYCRODOSE THERAPEUTICS INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| US-20210076956-A1 | Methods and Compositions for Restoring Homeostatic Capacity of a Subject | Palo Alto Investors LP | 2021-03-18 | — | — | US | disclosed |
| US-10835134-B2 | Methods and compositions for restoring homeostatic capacity of a subject | PALO ALTO INVESTORS (US) | 2020-11-17 | — | — | US | disclosed |
| US-10478492-B2 | Modifications of therapeutic agents for enhanced delivery to target sites | CLARIA PARTIKULA LLC (US) | 2019-11-19 | — | — | US | disclosed |
| US-10006005-B2 | Culture medium and method for inducing differentiation of pluripotent stem cells to hepatoblasts | NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20180028647-A1 | MODIFICATIONS OF THERAPEUTIC AGENTS FOR ENHANCED DELIVERY TO TARGET SITES | CLARIA ODIN LLC | 2018-02-01 | — | — | US | disclosed |
| US-20170349949-A1 | METHODS OF SELECTING SUBJECTS FOR TREATMENT WITH METABOLIC MODULATORS | CLARIA PARTIKULA LLC | 2017-12-07 | — | — | US | disclosed |
| US-20160053230-A1 | Culture Medium And Method For Inducing Differentiation of Pluripotent Stem Cells To Hepatoblasts | NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY (JP) | 2016-02-25 | — | — | US | disclosed |
| US-20150359888-A1 | Methods and Compositions for Restoring Homeostatic Capacity of a Subject | PALO ALTO INVESTORS | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026731-A1 | TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT | HTR7, HTR6, PNMT | SLC25A1 1861/4885MEN1 1233/4885KMT2A 789/4885 |
| US-20240358783-A1 | METHOD AND SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF A PSYCHEDELIC AGENT | HTR7, HTR6, PNMT | SLC25A1 2070/4885MEN1 1350/4885KMT2A 896/4885 |
| US-20180028647-A1 | MODIFICATIONS OF THERAPEUTIC AGENTS FOR ENHANCED DELIVERY TO TARGET SITES | PDK1, PC, PDK2 | SLC25A1 79/4885MEN1 1378/4885KMT2A 1257/4885 |
| US-10478492-B2 | Modifications of therapeutic agents for enhanced delivery to target sites | PDK1, PC, PDK2 | SLC25A1 79/4885MEN1 1378/4885KMT2A 1257/4885 |
| US-20220323389-A1 | TREATING NON-ALCOHOLIC FATTY LIVER DISEASE AND INFLAMMATORY STEATOHEPATITIS WITH SLC25A1 INHIBITORS | SLC10A1, SLC27A1, SLC25A3 | SLC25A1 16/4885MEN1 4426/4885KMT2A 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.